Predictive Oncology and Cancer Research Horizons Partner for Cancer Drug Development

Cancer Research Horizons announced on March 17, 2023 that it has partnered with Predictive Oncology to drive the development of oncology drugs. The collaboration will use Predictive Oncology’s PEDAL artificial intelligence and machine learning platform technology to determine which cancer types and patient populations are most likely to respond to treatment with Cancer Research Horizon’s pre-clinical drug inhibitors of glutaminase. By addressing tumor heterogeneity during pre-clinical stages, the probability of clinical success increases, according to Predictive Oncology.

The agreement joins together non-profit and industry and offers the potential for Cancer Research Horizons to incorporate PEDAL technology into future drug discovery processes.

“Our collaboration with Cancer Research Horizons represents a fundamental shift in drug discovery that could lead to the accelerated development of cancer therapies using compounds originating from the CRUK network and developed by Cancer Research Horizons in partnership with their global network,” said Raymond F. Vennare, CEO of Predictive Oncology, in a company press release. “We now have the ability to impact the most critical stage of early drug discovery in a way that has never been done before.”

“We are committed to working closely with scientists to discover and advance therapies that can help in the fight against cancer. Ensuring that patients receive the right treatment for them is of paramount importance and is why we are excited to work with Predictive Oncology to identify the most suitable population for the further development of our compounds. We look forward to applying Predictive Oncology’s expertise, enabling technology and dedication to progress exciting cancer therapeutics,” explained Tony Hickson, chief business officer for Cancer Research UK and Cancer Research Horizons, in the release. “We consider the potential of this collaboration a win for patients not just in the UK or US, but worldwide.”

Source: Cancer Research Horizons